ISSN : 2663-2187

Laboratory Indicators in Urinary Bladder and Renal Cell Cancer Patients Treated With Immune-Oncological Drugs.

Main Article Content

Mrs. Shilpa Kushte, Dr. Rachna, Dr. Amit Joshi Dr. P. G. Subramanian, Dr. Kinjalka Ghosh, Dr. Santosh Menon,Mr. Akash Pawar,Dr. Prashant Tembhare
» doi: 10.33472/AFJBS.6.6.2024.8005-8027

Abstract

Background: Urinary bladder (UB) and Renal Cell Carcinoma (RCC) are common in men than women with poor outcome. The novel immunotherapy (IT) drugs like Immune Check Point Inhibitors (ICIs) are effective but expensive. However, a cost-effective and reliable biomarker to predict response and clinical outcomes is lacking.Objective: To study the association of biochemical parameters, histopathological type, grades, number of immunotherapy cycles and demographic factors (age and gender) with Progression Free Survival (PFS) and Overall Survival (OS) in urinary bladder and renal cell Carcinoma patients treated with immune check point inhibitors. Method: It is a retrospective analysis. We included 52 patients with Urinary bladder and Renal Cell Carcinoma treated with immune check point inhibitors and the patients registered at Tata memorial cente from Jan 2008 to Dec 2019. Clinical evaluation and laboratory investigations were performed as a part of standard protocol. Laboratory parameters like Albumin(A), Globulin(G), Albumin Globulin Ratio(AGR), Histopathological Report (HPR) and tumour grade(low and high) of the Urinary bladder and Renal Cell Carcinoma were studied at the time of Tata Memorial Centre enrolment (TMH Enrol) and before the start (pre-treatment) of the immune check point inhibitors therapy. Results: Amongst the biochemical parameters, the pre-treatment Albumin Globulin Ratio was significantly associated with overall survival of the disease with p-value 0.035; hazard ratio 2.196 (95% CI – 1.057- 4.564). The progression free survival was not significant with p-value 0.093; hazard ratio 1.867 (95% CI – 0.901- 3.869) in the pre- treatment Albumin Globulin Ratio.The median-based cut off for Albumin Globulin Ratio at pre- immune check point inhibitors therapy was found to be 1.1 (IQR 0.9-1.3) to differentiate between progressed and non-progressed cases with 53.3% sensitivity and 55.6% specificity and for overall survival, the sensitivity and specificity was 56.7% and 61.1% respectively.When demographic parameters like age and gender was analysed, there was no significant association with progression free survival and overall survival of disease. Also the progression free survival and overall survival of disease were not significant in histopathology type (Urinary bladder and Renal Cell Carcinoma) and tumour grade (low and high). The number of immunotherapy cycles were significantly associated with progression free survival with p = 0.029: hazard ratio 0.457 (95.0% CI 0.226 - 0.921) but not with overall survival of the disease. Conclusion: Simple, routinely available and cost effective Albumin Globulin Ratio from biochemical test has a great potential to be used as a biomarker to predict the overall survival in patients with urinary bladder cancer and Renal Cell Carcinoma patients treated with immune check point inhibitors.

Article Details